OP here — wow, did not expect this much response! Thank you all for the thoughtful replies on GLP-1 therapy in patients.
To answer mel_PDX: I get my labs done through Quest every 3 months.
Quick update: my latest labs came back even better. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏
Relevant to GLP-1 therapy in patients over — here is my latest bloodwork comparison:
Key improvements: A1C 8.0% → 5.3%, triglycerides 211 → 111 mg/dL, hsCRP 6.0 → 1.1 mg/L. All on tirzepatide for 15 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.
Yep. My endo said the same thing about GLP-1 therapy in.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsSlightly tangential to GLP-1 therapy in patients but quinn_sf reminded me — has the insurance landscape changed recently?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.
GraceAZ_72 said:Thank you all for the thoughtful replies on GLP-1 therapy in patients
This is exactly right. GraceAZ_72 articulated what I have been trying to explain to my friends for months. The GLP-1 therapy in patients aspect is what made the difference for me.